Adalyon Appoints Former Novo Nordisk Director as CEO to Advance AI-Powered Speech Biomarkers for Clinical Trials
核心洞察
Adalyon (搜索), a tech-bio company developing AI-powered speech biomarker platforms, has appointed Ulrik Zeuthen as CEO to drive growth in clinical trial optimization technologies.
The company's proprietary speech-based digital biomarkers aim to address the 40-50% dropout rates in clinical trials by providing non-invasive, high-frequency monitoring of cognitive and behavioral changes.
Zeuthen brings pharmaceutical industry experience from Novo Nordisk and will lead efforts to establish partnerships with pharmaceutical companies seeking to improve patient stratification and retention in clinical research.
Adalyon (搜索), a Finland-based tech-bio company developing AI-powered speech biomarker platforms for clinical drug development, announced the appointment of Ulrik Zeuthen as Chief Executive Officer. The leadership change positions the company to expand partnerships with pharmaceutical companies seeking to optimize clinical trial outcomes through advanced behavioral analytics.
Zeuthen brings extensive pharmaceutical industry experience, having previously held Director-level positions at Novo Nordisk in Denmark and Japan, where he was responsible for establishing and executing partnerships with technical partners to drive scaled AI use case delivery. He also served as a data strategist at Deloitte and holds a Master of Science in Economics from the University of Copenhagen.
Addressing Clinical Trial Challenges Through Speech Analysis
Current clinical trial methodologies for measuring behavioral phenomena and drug response signals rely heavily on questionnaires and invasive samples, which are often episodic, rigid, and burdensome for participants. This approach contributes to dropout rates reaching 40-50% and frequently results in incomplete and biased data, according to the company.
Adalyon (搜索)'s technology aims to address these challenges by providing a non-invasive, high-frequency signal that improves sensitivity, reduces noise, and accelerates go/no-go decisions. The platform seamlessly integrates into existing trial processes to enable sponsors to recruit and retain appropriate participants while monitoring them more effectively for earlier detection of treatment responses.
"I'm excited to join Adalyon (搜索), to leverage the deep expertise of the team and the company's strong heritage in behavioral science and technology R&D for real impact," said Zeuthen. "Adalyon's proprietary methodology utilizing modern AI/ML capabilities in highly regulated environments stands out as market shaping. We're pioneering quantified behavioral analytics to modernize clinical research."
Technology Platform and Applications
The company's proprietary AI-based technology converts speech and text into quantitative biomarkers that capture subtle cognitive and emotional changes in trial participants. Using advanced natural language processing (NLP), large language models (LLMs), and its proprietary Ayda Insights behavioral analytics AI, Adalyon (搜索) extracts real-time, unbiased intelligence from natural speech.
The solution is designed as a "plug and play" technology that seamlessly integrates into existing trial infrastructures to complement, rather than replace, traditional data collection methods. This approach helps reduce participant burden and dropout rates while delivering measurable quality-of-life insights and enabling more efficient, outcome-driven trials.
Zeuthen emphasized the platform's potential for improving clinical trial outcomes: "Our adaptable 'patient-centric' approach is designed as a plug-and-play technology, driving better patient stratification and retention in trials, and with the potential to identify benefits in additional indications, enabling product label extensions and early detection of treatment effects."
Leadership Transition and Strategic Direction
Company founder Katarina Cantell will transition to the role of Chief Scientific Officer. Dr. Cantell holds a PhD in information systems and conducted doctoral research at Stanford University at the intersection of behavioral sciences and technology. She brings over 20 years of experience in digital health and strategic leadership, including executive roles at Aava Medical (搜索) and TietoEvry (搜索).
"Ulrik's expertise in applying AI/ML & analytics in life sciences together with his entrepreneur background and growth mindset makes him ideal to lead Adalyon (搜索) into its next chapter as we seek partnerships with pharmaceutical companies," said Dr. Cantell. "Adalyon's proprietary speech-based digital biomarker technology is designed to capture the true voice of the patient, not just what their blood tests may say. We could say that speech is the new blood, and we're using it to strive for a digital revolution in clinical drug development."
The company is actively seeking collaborations with pharmaceutical partners and clinical research organizations to enable more effective patient stratification and retention, earlier detection of treatment effects, and deliver more data-driven, patient-centric outcomes. With offices in Espoo, Finland, and Copenhagen, Denmark, Adalyon (搜索) is led by a multidisciplinary team of experts in behavioral science, AI engineering, and computational linguistics.